We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
- Authors
Goldstein, Daniel A.; Bilal, Usama; Prasad, Vinay
- Abstract
The KEYNOTE 024 trial compared the safety and efficacy of pembrolizumab versus chemotherapy in the first line setting of PD‐L1 positive metastatic NSCLC and suggested an impressive survival benefit with pembrolizumab. The high level of censoring in the trial casts considerable uncertainty on the actual magnitude of the benefit provided with this treatment.
- Subjects
PEMBROLIZUMAB; MONOCLONAL antibodies; LIGANDS (Biochemistry); LUNG cancer; MEDICAL care standards
- Publication
Cancer (0008543X), 2017, Vol 123, Issue 20, p3872
- ISSN
0008-543X
- Publication type
letter
- DOI
10.1002/cncr.30868